STERIS plc (STE) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-05-29

Business type: Franchise

How it makes money

It manages a $490.7 million backlog of capital equipment orders, with $392.1 million from the Healthcare segment, while prioritizing recurring revenue from consumables and services.

It earns through three segments. Healthcare provides operating room infrastructure like surgical tables and sterilizers. AST provides contract sterilization for medical device manufacturers. Life Sciences supports biopharmaceutical aseptic manufacturing.

Profit is driven by the recurring need for cleaning chemistries and instrument repair services after capital equipment is installed. The company focuses on the aging population and increased demand for medical procedures like endoscopies to drive volume.

What protects it: the moat

A global network of contract sterilization facilities and 2,402 patents in foreign jurisdictions protect its earnings from competitors in the highly regulated medical device industry.

Management claims its competitive position is maintained through technical know-how and a global facility footprint located near medical device clusters. The industry is highly regulated by the FDA and EPA, creating significant barriers to entry.

Its large installed base of capital equipment leads to long-term service contracts and repeat consumable sales. These specialized offerings, like proprietary cleaning chemistries and endoscopy accessories, are difficult for smaller rivals with limited product portfolios to displace.

What growth costs

In fiscal 2026, it spent $369.0 million on capital expenditures and $23.4 million for acquisitions to expand its Healthcare segment product and service offerings.

It must reinvest to maintain and grow its global infrastructure. Specifically, it is expanding irradiation processing capacity using accelerator-based technologies to mitigate risks associated with the supply of cobalt-60.

Acquisitions are a core part of the long-term growth strategy. In fiscal 2026, it completed two tuck-in acquisitions and made a $134.0 million noncontrolling equity investment in a non-U.S. healthcare product manufacturer.

What could damage it

The One Big Beautiful Bill Act could reduce Medicaid funding, potentially causing its hospital customers to curtail purchases of capital equipment and services.

Since much of the revenue comes from healthcare providers, any significant change in government reimbursement levels or healthcare policy can impair earnings. Constraints on public budgets can prevent hospitals from upgrading surgical suites or maintaining high-volume sterilization services.

Changes to the USMCA could also impair its manufacturing operations in Canada and Mexico, potentially impacting its ability to source materials or market products at competitive prices.

About STERIS plc

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, equipment management services, and connectivity solutions; and various preventive maintenance programs, repair services, custom process improvement consulting, and outsourced instrument sterile processing, as well as instrument, devices, and endoscope repair and maintenance services. It also provides process controls and monitoring systems, as well as integrated sterilization equipment, such as accelerators, product handling, and automation; and sterilization modalities, product development, materials testing, and process validation, as well as support services for sterilization equipment and control systems comprising installation, preventive maintenance, updates, repairs, and troubleshooting. In addition, the company offers pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators; and preventive maintenance programs and repair services to support the operation of capital equipment. It serves healthcare providers, medical device and pharmaceutical manufacturers, biopharmaceutical manufacturing facilities, and hospitals. The company was formerly known as New STERIS Limited and changed its name to STERIS plc in November 2015. STERIS plc was founded in 1985 and is headquartered in Mentor, Ohio.

More on STE

Other companies in Medical Devices